These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Javitt DC Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858 [TBL] [Abstract][Full Text] [Related]
3. Recent advances in the neurobiology of schizophrenia. Miyamoto S; LaMantia AS; Duncan GE; Sullivan P; Gilmore JH; Lieberman JA Mol Interv; 2003 Feb; 3(1):27-39. PubMed ID: 14993436 [TBL] [Abstract][Full Text] [Related]
4. Schizophrenia: diverse approaches to a complex disease. Sawa A; Snyder SH Science; 2002 Apr; 296(5568):692-5. PubMed ID: 11976442 [TBL] [Abstract][Full Text] [Related]
5. Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder. Gogos JA Int Rev Neurobiol; 2007; 78():397-422. PubMed ID: 17349868 [TBL] [Abstract][Full Text] [Related]
6. The biological basis of schizophrenia: new directions. Weinberger DR J Clin Psychiatry; 1997; 58 Suppl 10():22-7. PubMed ID: 9265913 [TBL] [Abstract][Full Text] [Related]
7. Phenotype of schizophrenia: a review and formulation. Tamminga CA; Holcomb HH Mol Psychiatry; 2005 Jan; 10(1):27-39. PubMed ID: 15340352 [TBL] [Abstract][Full Text] [Related]
8. Role of calcium regulation in pathophysiology model of schizophrenia and possible interventions. Yarlagadda A Med Hypotheses; 2002 Feb; 58(2):182-6. PubMed ID: 11812200 [TBL] [Abstract][Full Text] [Related]
9. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Guillin O; Demily C; Thibaut F Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867 [TBL] [Abstract][Full Text] [Related]
10. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development. Marek GJ Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861 [TBL] [Abstract][Full Text] [Related]
11. [New pharmacological approaches to the treatment of schizophrenia]. Uzbay IT Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368 [TBL] [Abstract][Full Text] [Related]
12. Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. Martins-de-Souza D J Psychiatr Res; 2010 Feb; 44(3):149-56. PubMed ID: 19699489 [TBL] [Abstract][Full Text] [Related]
13. Recognition and optimal management of schizophrenia and related psychoses. Singh B Intern Med J; 2005 Jul; 35(7):413-8. PubMed ID: 15958112 [TBL] [Abstract][Full Text] [Related]
15. Time course of the antipsychotic effect in schizophrenia and some changes in postmortem brain and their relation to neuroleptic medication. Crow TJ; Cross AJ; Johnstone EC; Longden A; Owen F; Ridley RM Adv Biochem Psychopharmacol; 1980; 24():495-503. PubMed ID: 6105795 [No Abstract] [Full Text] [Related]
16. [Pathophysiology of schizophrenia and its impact on pharmacotherapy]. Widschwendter CG; Fleischhacker WW Fortschr Neurol Psychiatr; 2005 Nov; 73 Suppl 1():S32-7. PubMed ID: 16270242 [TBL] [Abstract][Full Text] [Related]
17. [Prevention of schizophrenia]. Kéri S; Janka Z Orv Hetil; 2004 Jan; 145(2):59-65. PubMed ID: 14978876 [TBL] [Abstract][Full Text] [Related]
18. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? Large CH J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656 [TBL] [Abstract][Full Text] [Related]